沙库巴曲缬沙坦治疗慢性射血分数降低心力衰竭35例临床观察  

Clinical observation of sacubitril-valsartan in chronic heart failure with reduced ejection fraction

作　　者：柯子奋 梁妍 张芝帅 李庆军[1] 温志桥[1] 龙清霞 KE Zi-fen;LIANG Yan;ZHANG Zhi-shuai;LI Qing-jun;WEN Zhi-qiao;LONG Qing-xia(Department I of Cardiology,Zhanjiang Central People’s Hospital,Zhanjiang 524045,China)

机构地区：[1]广东省湛江中心人民医院心内一科

出　　处：《广东医科大学学报》2019年第3期335-338,共4页Journal of Guangdong Medical University

基　　金：湛江市科技计划项目(No.2017B01017)

摘　　要：目的观察沙库巴曲缬沙坦治疗慢性射血分数降低心力衰竭(HFrEF)的效果。方法70例慢性HFrEF患者接受常规抗心力衰竭治疗,其中对照组、观察组分别使用血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂、沙库巴曲缬沙坦。比较两组的疗效、N末端B型利钠肽原(NT-proBNP)、醛固酮、心肌肌钙蛋白I(cTnI)、心脏彩超结果和不良反应。结果观察组的疗效明显优于对照组(P<0.05)。观察组治疗后NT-proBNP、醛固酮和cTnI水平均低于对照组;左心室射血分数明显高于对照组(P<0.05或0.01)。结论沙库巴曲缬沙坦治疗慢性HFrEF可提高疗效、射血分数,降低神经内分泌因子水平。Objective To observe the efficacy of sacubitril-valsartan in chronic heart failure with reduced ejection fraction (HFrEF). Methods Seventy patients with chronic HFrEF received conventional anti-heart failure treatment and angiotensin-converting enzyme inhibitor/angiotensin II receptor antagonist (control group) or sacubitril-valsartan (observation group). Therapeutic efficacy, adverse reactions, levels of N-terminal B-type natriuretic peptide (NT-proBNP), aldosterone, cardiac troponin I (cTnI), and echocardiography were compared between 2 groups. Results Compared with control group, therapeutic efficacy and left ventricular ejection fraction were increased (P<0.01 or 0.05), while NT-proBNP, aldosterone and cTnI levels decreased (P<0.01 or 0.05) in observation group. Conclusion Sacubitril-valsartan can improve curative effect and ejection fraction and reduce neuroendocrine factors in patients with chronic HFrEF.

关 键 词：心力衰竭 射血分数 沙库巴曲缬沙坦 

分 类 号：R541[医药卫生—心血管疾病]